Voyager Therapeutics (VYGR) AI Stock Analysis

Voyager Therapeutics

(BMV:VYGR)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

CNS Delivery PlatformVoyager’s specialized AAV capsid and CNS delivery capabilities provide a focused technological foundation for its genetic-medicine pipeline. If these tools translate into effective, targeted treatment delivery, they can support multiple neurological programs and create durable platform value beyond a single product.

Negative Factors

Revenue ContractionThe sharp, multi-period revenue decline indicates that Voyager’s current commercial or partnered revenue base has weakened materially. Lower revenue reduces internal funding capacity and increases reliance on successful pipeline progress, future partnerships, or external financing to support ongoing operations.

Voyager Therapeutics (VYGR) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 105.98M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.9
Beta (1Y): -0.44
Revenue Growth: -23.70%
EPS Growth: 11.51%
Country: Mexico
Employees: 141
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Pha...

Voyager Therapeutics Earnings Call Summary

Earnings Call Date:Mar 10, 2025(Q4-2024)|% Change Since:-80.00%|Next Earnings Date:Nov 09, 2026

Earnings Call SentimentPositive

The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.

Positive Updates

Strong Cash Position and Potential Milestone Payments

Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.

Negative Updates

Setback in SOD1 Silencing Gene Therapy Program

The SOD1 silencing gene therapy program moved back into the research stage due to the payload not meeting the target profile, requiring the identification of a new payload.

Company Guidance

During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.

Voyager Therapeutics Risk Analysis

Voyager Therapeutics disclosed 74 risk factors in its most recent earnings report. Voyager Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.We are subject to a number of risks that could adversely affect our business, results of operations, financial condition and future prospects, including those identified in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026. Any of the risks and uncertainties described in our Annual Report on Form 10-K could materially and adversely affect our business, financial condition, results of operations and future growth prospects, and such risks and uncertainties are not the only ones we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations. Please see the discussion under the caption “Forward-Looking Statements” in this Quarterly Report on Form 10-Q for a discussion of some of the forward-looking statements that are qualified by these risk factors.Q2, 2026

Voyager Therapeutics Peers Comparison

Overall Rating

Financial Indicators

MX:VYGR against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:VYGR and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	MX:VYGR	Voyager Therapeutics Inc.	30.00	-63.00	-67.74%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Voyager Therapeutics AI Stock Analysis